Evidence map›Paper›PMID 31558788›Full record

ArticleBone marrow transplantation2020

EASIX and mortality after allogeneic stem cell transplantation.

Thomas Luft, Axel Benner, Tobias Terzer, Sonata Jodele, Christopher E Dandoy, Rainer Storb, Lambros Kordelas, Dietrich Beelen, Ted Gooley, Brenda M Sandmaier and 5 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Bone marrow transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05502887 (The Endothelial Cell Dysfunction and Outcome Project for Hematological Neoplasms), which is not on this map. Cited by 113 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05502887 recruitingnot on this mapstarted 2022, after this paper: background citation

The Endothelial Cell Dysfunction and Outcome Project for Hematological Neoplasms (EndoCDO-H). A Prospective Registry Study on Endothelial Functional Profile, Intervention Type and Clinical Outcome in Patients With Hematological Neoplasms

TypeobservationalSponsorProf. Dr. Thomas LuftRan2022 to 2032Enrolled1,000ConditionsHematological Neoplasm, Endothelial DysfunctionArmsSublingual in vivo microscopy with the Glycocheck microscope
3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 1 synthesis or guideline pooled it, 145 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Thomas LuftMedicine V, University Hospital Heidelberg, Heidelberg, Germany. thomas.luft@med.uni-heidelberg.de.
Axel BennerDivision of Biostatistics, German Cancer Research Centre, Heidelberg, Germany.
Tobias TerzerDivision of Biostatistics, German Cancer Research Centre, Heidelberg, Germany.
Sonata JodeleOncology, Hematology, Cincinnati Children's Hospital Medical Centre, Cincinnati, OH, USA.
Christopher E DandoyOncology, Hematology, Cincinnati Children's Hospital Medical Centre, Cincinnati, OH, USA.ORCID http://orcid.org/0000-0002-4001-9203
Rainer StorbFred Hutchinson Cancer Research Centre, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-9343-4099
Lambros KordelasDepartment of Bone Marrow Transplantation, West German Cancer Centre, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany.ORCID http://orcid.org/0000-0003-3116-473X
Dietrich BeelenDepartment of Bone Marrow Transplantation, West German Cancer Centre, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany.
Ted GooleyFred Hutchinson Cancer Research Centre, Seattle, WA, USA.
Brenda M SandmaierFred Hutchinson Cancer Research Centre, Seattle, WA, USA.
Mohamed SorrorFred Hutchinson Cancer Research Centre, Seattle, WA, USA.
Markus ZeisbrichDepartment of Nephrology, University of Heidelberg, Heidelberg, Germany.
Aleksandar RadujkovicMedicine V, University Hospital Heidelberg, Heidelberg, Germany.
Peter DregerMedicine V, University Hospital Heidelberg, Heidelberg, Germany.
Olaf PenackCharité Universitätsmedizin Berlin, Hematology, Oncology and Tumorimmunology, Berlin, Germany.
Heidelberg University · DEUniversity of Washington · USCincinnati Children's Hospital Medical Center · USGerman Cancer Research Center · DEUniversity of Duisburg-Essen · DEBerlin-Brandenburger Centrum für Regenerative Therapien · DE

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Geoffrey Roger HILL · 1985 to 2026
$128.4M
Project 3: Stem Cell Allografts for Lymphoid MalignanciesP01CA078902 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SANDMAIER, BRENDA MARIE · 1999 to 2025
$46.1M
Project 3: Gene Therapy for Correction of Blood DisordersP01HL122173 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KIEM, HANS-PETER · 2015 to 2019
$12.9M
Deutsche Forschungsgemeinschaft (German Research Foundation) PE1450/3-1Deutsche Forschungsgemeinschaft (German Research Foundation) TL820.8-1EC | EC Seventh Framework Programm | FP7 Coordination of Non-Community Research Programmes (FP7-GA - Coordination of Non-Community Research Programmes) EU306240NCI NIH HHS P01 CA018029NCI NIH HHS P01 CA078902NCI NIH HHS P30 CA015704NHLBI NIH HHS P01 HL122173
6 · The paper itself

Abstract

Allogeneic stem cell transplantation (alloSCT) is an effective immunotherapy in patients with hematological malignancies. Endothelial dysfunction was linked to major complications after alloSCT. We asked the question if the "Endothelial Activation and Stress Index" (EASIX; [(creatinine × LDH) ÷ thrombocytes]) can predict mortality after alloSCT. We performed a retrospective cohort analysis in five alloSCT centers in the USA and Germany. EASIX was assessed prior to conditioning (EASIX-pre) and correlated with mortality in 755 patients of a training cohort in multivariable models. The predictive model established in the training cohort was validated in 1267 adult allo-recipients. Increasing EASIX-pre predicted lower overall survival (OS) after alloSCT, and successful model validation was achieved for the validation cohort. We found that EASIX-pre predicts OS irrespective of established scores. Moreover, EASIX-pre was also a significant prognostic factor for transplant-associated microangiopathy. Finally, EASIX-pre correlated with biomarkers of endothelial homeostasis such as CXCL8, interleukin-18, and insulin-like-growth-factor-1 serum levels. This study establishes EASIX-pre based on a standard laboratory biomarker panel as a predictor of individual risk of mortality after alloSCT independently from established clinical criteria.

Indexed as

Hematologic NeoplasmsHematopoietic Stem Cell TransplantationAdultGermanyHumansRetrospective StudiesStem Cell TransplantationTransplantation ConditioningTransplantation, Homologous

Identifiers

PMID31558788
PMCPMC8082940
OpenAlexW2976365437

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.